To determine which genes may be activated or inactivated during breast cancer development, we employed two cloning strategies (subtractive hybridization and dierential display) using RNA samples from a human breast tumor and its matching normal breast cell line. Of 950 clones isolated, 102 cDNA inserts were analysed by DNA sequencing and database searching. We found 30 clones that were obviously unidenti®ed, with no signi®cant homology to any listed human gene. We focused upon one of the novel genes, Di12, that is dierentially expressed as a 1.35 kb RNA in breast cancer tissues and cell-lines, and in several normal tissues. A full length cDNA of this gene was cloned, and its DNA sequence revealed an open reading frame of 339 amino acids. Antibodies to the ten N-terminal amino acids were developed to investigate the expression of Di12 in breast cancer cell-lines and tumors. The Di12 protein was found in tissue sections of in®ltrating ductal carcinomas (IDCs), but not in benign or normal breast specimens. RT ± PCR analysis con®rmed expression of Di12 in 80% of in®ltrating ductal carcinomas (IDCs). As IDC constitutes *70% of breast cancers seen clinically, the level of Di12 expression may be predictive of disease progression.
Introduction
Oncogenes and tumor suppressor genes play critical roles in the development of malignancies (Harris et al., 1993) . Ampli®cation and activation of several oncogenes in primary breast tissues such as c-erb-B2 (HER-2/neu), c-MYC and INT2, have been previously implicated in malignant progression and subsequently evaluated for their prognostic potential (Allred et al., 1990; Berns et al., 1992) . Growth factor receptors and hormone induced genes have also been similarly investigated (Sainsbury et al., 1987; Iwase et al., 1994) . Unfortunately, the expression of these genes is often limited to a small percentage of breast carcinomas only, and thus their prognostic value remains unclear.
The recent discoveries that individuals with BRCA1 and BRCA2 mutations have a predisposition to breast cancer may facilitate the detection of an early onset type disease for hereditary breast cancer (Easton and Peto, 1993; Miki et al., 1994; Tavtigian et al., 1994) . The incidence of these cases however, is just 5 ± 10% of all known breast cancers (Easton and Peto, 1993; Miki et al., 1994; Tavtigian et al., 1994) . The need for markers which would discriminate molecular/biological dierences between primary and metastatic breast tumors remains pressing. Characterization of such factors would assist in identifying individuals at risk for agressive disease and aid therapeutic decisions.
In order to identify and isolate genes whose expression is associated with breast carcinomas in various stages of neoplastic development, we employed subtractive-hybridization cloning and dierential display-PCR (Schweinfest et al., 1990; Liang and Pardee, 1992; Salesiotis et al., 1995; Burger et al., 1996) . RNA was prepared from two breast cell-lines derived from a tumor and the adjacent normal tissue of the same patient. Speci®cally, cDNAs from the normal breast cell line, Hs578Bst, were subtracted from cDNAs of the breast carcinoma cell line, Hs578T. Over 950 clones were obtained by subtractive cloning and dierential display PCR. In all, 102 cDNAs were sequenced and analysed by computer searches and 30 were found to be unique. However, some of these novel genes showed identity with ESTs. Using Northern blot analysis of RNA prepared from various breast cancer cell-lines and primary tumors we found that several of the novel cDNAs are dierentially expressed, implying an association with breast cancer development (Burger et al., 1996) . One of these novel cDNAs, Di12, that may be associated with breast malignancy was therefore selected for detailed characterization based on its dierential expression pattern. The full length Di12 cDNA clone was isolated and speci®c antibodies were generated in order to study its distribution in patient breast-tumor samples. Our results show Di12 expression to be associated with in®ltrating ductal carcinomas, and expression was not detected in benign ®broadenoma or normal breast tissue samples.
Results

Cloning of breast cancer-associated genes
Using subtractive-hybridization techniques to identify genes linked to breast cancers, we generated cDNA libraries enriched for breast cancer-associated cDNAs. Single-stranded cDNA clones derived from a normal human breast cell-line, Hs578Bst, were subtracted using single-stranded cDNA clones of a breast carcinoma cell-line, Hs578T, derived from the adjacent malignant tissue of the same patient. A total of 950 clones from the breast cancer enriched cDNA subtraction library were obtained. DNA sequences of 78 clones with inserts greaters than 250 bp were determined and analysed by FASTA and BLAST programs (GCG, UW, Madison, WI and NIH, NLM, Basic Local Alignment Search Tool; Pearson and Lipman, 1988) . These analyses found 28 to be novel cDNAs having no signi®cant homology to known genes in GenBank (Table 1) . A second strategy for obtaining dierentially-expressed genes in breast cancer cells was to clone PCR-ampli®ed cDNAs reverse-transcribed from RNAs derived from the normal (Hs578Bst) and tumor (Hs578T, BT474 and BT20) breast cell-lines. The cDNAs that were reproducibly dierentially-expressed from these human breast cell-lines were cloned and sequenced. Twenty-four clones representing 7 unique fragments were compared to GenBank entries, and two were found to be novel genes. In order to determine if the novel cDNAs encode genes that may be involved in breast cancer, they were screened by Northern blot analysis of RNA derived from tumor and normal breast cell-lines. Dierential expressing patterns for 18 genes are shown in Table 2 .
Full length cDNA cloning and protein sequence analysis of Di12
A full-length Di12 cDNA (1363 bp) was cloned from a CEM cDNA library. The DNA sequence contains an open reading frame of 339 amino acids in which the ®rst ATG, (G-C-C-A-T-G-G) is homologous to the Kozak consensus (A/G-X-X-A-T-G-G) (Kozak et al., 1981) ; the protein translation start site (Figure 1 ). Using the GCG UW MOTIFS program we found: four consensus (N-X-S/T) N-glycosylation sites at positions 62, 65, 196, 277 ; six CkII sites (consensus S/T-X-X-D/ E) at positions 67, 137, 163, 189, 199 and 235 ; seven PKC sites (consensus S-X-K) at positions 7, 10, 100, 124, 165, 189 and 248; and various myristoylation sites. The PEPPLOT program predicts several hydrophobic regions in the Di12 protein, including a hydrophobic tail at the C-terminus.
To con®rm the open reading frame, the Di12 cDNA was subcloned into the pSG5 expression vector for use in an in vitro coupled transcription-translation system. As expected, a 35 kD protein was produced with the vector containing the Di12 insert (Figure 2 , lane 1), but not with the control vector (pSG5) minus the insert (data not shown). The 35 kD expressed product is also recognized by antiDi12 antibodies in immunoprecipitation assays ( Figure   2 , lanes 3 and 4) and not by preimmune serum ( Figure  2 , lane 2).
Expression of Di12 mRNA
The Di12 gene was found to be expressed as a 1.35 kb mRNA in several breast cancer cell-lines. The highest levels of expression were observed in BT483 ( Figure  3a , lane 1); there were lower levels seen in Hs578T ( Figure 3b , lane 2), and very little or no expression at all in HTB26, BT-20 and T47D cell-lines (Figure 3a and b). Di12 expression was undetectable in the normal mammary gland cell line CRL 7370 ( Figure  3a , lane 3), and was barely detectable in another normal breast cell line Hs578Bst (e.g., only after prolonged exposures using increased amounts of poly(A) RNA (data not shown)). Di12 RNA was found to be expressed in various normal human ( Figure 3c ) and rat ( Figure 3d ) tissues, including lung, kidney, pancreas and heart, but it was expressed at low levels or was not detectable at all in the brain, placenta and liver. The similarity of expression patterns of Di12 in both rat and human tissues, indicates that this gene is likely to be functionally conserved between mammalian species. 
Di12 expression is associated with in®ltrating ductal carcinomas
In order to determine if Di12 is dierentially expressed in dierent types of breast cancer or if it is stage related, we used immunohistochemistry and RT ± PCR. Tissue samples were obtained from normal breast, ®broadenomas and ®brocystic disease with nonproliferative and proliferative changes, both with or without atypia, as well as ductal carcinomas in situ and in®ltrating ductal carcinomas. Paran embedded sections of the breast cancer cell-lines BT483 and Hs578T, which produce high and low levels of Di12 RNA respectively (Figure 3) , were included as positive controls.
A total of 47 paran embedded normal and malignant primary breast tissues were screened for tissue distribution of Di12 gene product. In particular, six normal breast tissues from breast reductions, ®ve lobular carcinomas in situ, three ductal carcinomas in situ and 33 IDCs of various grades and stages of disease progression were examined. A representative panel of immunostained sections from cell line and tissue samples is shown (Figure 4) . Strong brown Di12-speci®c staining was seen in the cytoplasm of cells in every IDC section, with a slight increase in the perinuclear regions of less well-dierentiated cells with poor prognosis (Figure 4e ± g ). In contrast, normal breast tissue (Figure 4h) showed only purple nuclear counterstain, with no Di12-speci®c staining. As expected, BT 483 cells showed the strongest Di12 protein staining (Figure 4a and d) ; whereas Hs578T, with lower levels of Di12 RNA expression, showed weaker staining using Di12 antibody (Figure 4c) .
We used RT ± PCR in order to complement the Di12 protein expression data and con®rm its dierential expression in dierent types of breast cancer tissues. Samples were examined from normal breast, fibroade- nomas and ®brocystic disease with non-proliferative and proliferative changes, and those with or without atypia, as well as ductal carcinomas in situ and in®ltrating ductal carcinomas. Our results show that Di12 expression is associated with more than 80% of the con®rmed IDC specimens, and its expression was absent in non-malignant samples ( Figure 5 ). Interestingly, the only Di12-negative IDC specimen was in fact described histologically as having extensive tissue necrosis, with a single intraductal papilloma localized 
Discussion
In the development of breast neoplasia there are limited subsets of genes that will be speci®cally expressed at various stages. Only a certain number of these will be critical for the progression of malignancy, especially those associated with the metastatic spread of this disease. Once identi®ed, such dierentially expressed genes (Table 2) will be useful for diagnosis and for monitoring disease progression, as well as for facilitating the molecular de®nition of speci®c stages of tumor development. This information will also assist in patient prognosis as well as in the selection of various treatment modalities. In addition, molecular de®nition of new genes involved in breast tumors will yield novel targets for gene therapy and for therapeutic intervention. The study described here, using both subtractivehybridization and dierential display-PCR yielded 30 novel genes that may prove useful in de®ning dierences between normal and breast cancer tissues at the molecular level (as determined from RNA and protein expression by Northern blot analysis, RT ± PCR and immunohistochemistry). Collectively these novel genes provide us with potentially new molecular markers. This study also revealed several known genes encoding speci®c growth factors, their receptors, protein kinases, and transcription factors or tumor suppressors, which may be involved in signal transduction and/or play (an) important role(s) in normal breast and tumor development (cf. Table 1 ). Several of the known cDNAs, including c-fgr, E2A, osteonectin, mac25, and GAP SH3 binding protein, have been reported to be involved in breast and other cancers (Abts et al., 1991; Murre et al., 1989; Shimasaki et al., 1991) . One of the novel genes, Di12, was characterized in detail and RT ± PCR and immunohistochemistry were used to examine its potential as a tumor marker in breast malignancies. The evaluation of Di12 gene expression in breast carcinomas showed that it is predominantly associated with the tumors of the in®ltrating ductal type, but not with ductal carcinoma in situ, benign ®broadenomas, or normal breast tissue obtained from reduction mammoplasty. Moreover the Di12 antibody data were in close agreement with RT ± PCR and Northern blot data obtained from cell-lines and primary tissues. Both by Northern blot and immunohistochemistry, high and low levels of Di12 expression were found in BT483 and Hs578T breast cancer cell-lines respectively. Similarly a good correlation of Di12 gene expression by RT ± PCR, was observed along with the positive staining of Di12 protein by immunoperoxidase technique in primary tissues, further con®rming the sensitivity and accuracy of each of the methods employed. In general cytoplasmic distribution of Di12-speci®c protein was seen throughout in®ltrating pleomorphic cells, and malignant cells invading vascular spaces, but not in normal cells. Collectively these results suggest that Di12 gene expression is indeed associated with advanced and aggressive disease, notably IDCs. The function of Di12 protein remains undetermined at the present time. However, the data derived from clinical specimen suggests that the Di12 product may become a useful prognostic marker for invasive ductal carcinomas. Since the IDC constitutes more than 70% of routine clinical specimens, a positive marker for IDC as we describe could be useful in the diagnosis and management of patients after primary resection; it could also be used to identify, at an early stage, those women who might bene®t from a more aggressive therapeutic protocol. Large scale screening of clinical samples is in progress to assess the predictive value of the presence or absence of Di12 gene product both for its relationship to the progression of breast cancer disease, as well as its potential as a diagnostic/ prognostic indicator of metastasis.
Finally the hypothesis that there are subsets of genes dierentially expressed and regulated in discrete stages of breast cancers compared to normal cells, is typi®ed, and perhaps vindicated by the clinical association of increasing Di12 with progressively worsening IDCs. Whether the overexpression of such genes arises as a consequence of, or directly from mutations and/or other gene aberrations remains to be determined. Further investigation of the molecular alterations associated with the expression of Di12 as well as all the other novel genes ( Tables 1 and 2 ) that take place in normal breast and breast carcinomas may eventually provide new insight into the understanding of the biology of breast cancer which may then lead to the development of newer and more eective methods in the treatment and prevention of this malignant disease.
Materials and methods
Cell-lines
The human breast cancer and normal breast cell-lines were obtained from the ATCC (Rockville, MD).
Subtractive cloning
The lambda ZAP II phagemid system (Stratagene, La Jolla CA) was used for the construction of directional libraries in opposite orientation using the EcoRI and XhoI sites. cDNA's were prepared from the`normal' breast cell line Hs578Bst and the tumor cell line Hs578T as described (Schweinfest et al., 1990; Salesiotis et al., 1995; Burger et al., 1996) .
Di12 (415 bp)
PBGD (490 bp) Figure 5 Expression of Di12 in normal and breast cancer tissue samples. RT ± PCR of identical cDNA samples from various normal and benign breast tissues were carried out with Di12 speci®c primers (top) and the housekeeping gene, porphobilinogen deaminase (PBGD, bottom). PCR-ampli®ed products were analysed on a 2% agarose gel. Lanes 1, 2, 3, and 9 contain IDC samples. Lane 6 contains intraductal papilloma sample, lane 4 contains benign tissue and samples in lanes 7, 8 and 10 are derived from ®broadenomas
Dierential display
The dierential display using the RNA prepared from normal (Hs578Bst) and breast cancer cell-lines (Hs578T, BT474, and BT20) using a kit from GenHunter Corp., (Brookline, MA) (Liang and Pardee, 1992) . DNA from dierentially displayed bands of interest were recovered, reampli®ed and cloned into pBS or TA cloning vectors (Stratagene or Invitrogen, San Diego, CA, respectively) and further characterized by DNA sequence analysis and Northern blotting.
cDNA cloning
A Clontech CEM cDNA library was screened with a partial cDNA for Di12 by standard techniques (Sambrook et al., 1989) .
Northern blotting and RT ± PCR
Total RNA from breast cancer cell-lines or tissues was isolated using the RNAzol B method, and probed with cDNA fragments as described previously (Salesiotis et al., 1995; Burger et al., 1996) . Tissue RNAs were reversetranscribed and PCR ampli®cations were performed with Di12 speci®c primers (sense: 5'-CGG CTG CTG GTG CTG ATT TG-3') and (anti-sense: 5'-CCA CGT GTC GCG TCA CCA AT-3') designed to generate a 415 bp product. PCR ampli®cations were performed in 30 ml reactions containing 10 ml of cDNA sample, 100 ng each primer, 200 mM each dNTP, 10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 0.1 mg/ml gelatin and 2.5 U taq DNA polymerase using 35 cycles of 948C (30 s), 558C (45 s), 728C (90 s), with a ®nal extension of 10 s at 728C.
Di12 antibodies
Antibodies were raised in rabbits against the N-terminal 10 amino acid synthetic peptide: MARDGASIKT (cf. Figure 1) .
Tissue samples
Forty-seven paran-embedded samples from breast tissues were obtained from the Pathology Department at Bradford Royal In®rmary (BRI). Ten fresh breast tissue samples for RNA isolation were provided by the Surgical Pathology Department at Women's College Hospital. All patient samples received were graded for the presence of malignancy by a pathologist to ensure accuracy of characterization. Utilization of patient material and diagnostic information was approved by the respective institutional ethical review committees.
Immunohistochemistry
Immunohistochemical localization of Di12 protein was examined in two paran-embedded breast cancer cell-lines and various primary tissue samples including thirty-three malignant IDCs, three DCIS, ®ve LCIS and six normal breast samples from reduction mammoplasties with the HistoStain TM SP Kit (rabbit, Zymed, San Francisco, CA) as described (Soubeyran et al., 1995) . The Elston-modi®ed Bloom and Richardson method was used for histological grading of breast tumors (Elston and Ellis, 1991) .
